Roadrunner Therapeutics

Roadrunner Therapeutics is a biotechnology company and a subsidiary of BridgeBio Pharma focused on the development of targeted protein degraders for oncology. The company's primary focus is on the discovery and advancement of molecular glue degraders that target GSPT1 (G1 to S phase transition 1), a translation termination factor. By inducing the selective degradation of GSPT1, the company aims to trigger apoptosis in cancer cells, particularly those driven by the Myc oncogene. Roadrunner operates within BridgeBio's hub-and-spoke model, which provides centralized corporate and R&D support to its asset-specific subsidiaries. The lead program is designed to address unmet needs in solid tumors and hematological malignancies.